Stock Events

Stock Events

Pharvaris NV 

$36.22
9
+$0.56+1.57% 18:05 Today

Statistics

Day High
36.38
Day Low
35.32
52W High
38.13
52W Low
20.65
Volume
175,045
Avg. Volume
515,484
Mkt Cap
2.54B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.98
-0.87
-0.77
-0.66
Expected EPS
-0.83386735824
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-202.18MNet Income

Analyst Ratings

50.29Average Price Target
The highest estimate is 75.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHVS. It's not an investment recommendation.
Microsoft
4
MSFT
Amazon
4
AMZN
Apple
3
AAPL
NVIDIA
3
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for patients with serious and life-threatening rare diseases and medical conditions, including genetic disorders, which is a similar focus area to Pharvaris' work on hereditary angioedema.
Takeda Pharmaceutical
TAK
Mkt Cap57.58B
Takeda Pharmaceutical Company Limited operates in various therapeutic areas, including rare diseases, which aligns with Pharvaris' focus on providing treatments for rare conditions like hereditary angioedema.
Carlisle Companies
CSL
Mkt Cap14.16B
CSL Behring is a global biotherapies leader which develops and delivers innovative therapies for people with rare and serious diseases, competing directly in the space of treatments for conditions like those Pharvaris targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics for the treatment of rare genetic diseases, which competes with Pharvaris' approach to targeting genetic disorders.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on developing therapies for neurological and neurodegenerative diseases, along with rare diseases, positioning it as a competitor in the rare disease sector.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics, Inc. is focused on the discovery and development of RNA-based therapeutics for the treatment of rare diseases, directly competing with Pharvaris' focus areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a global biotechnology company that develops and produces innovative human therapeutics, including treatments for rare diseases, making it a competitor in the rare disease therapeutic market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its development of treatments for serious medical conditions, including rare diseases, which places it in direct competition with Pharvaris in the rare disease market.

About

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Show more...
CEO
Berndt Modig
Employees
129
Country
Netherlands
ISIN
NL00150005Y4
WKN
000A2QNWS

Listings

MU
DE
9EN.MU
XNAS
US
PHVS
F
DE
9EN.F
BOATS
BOATS
PHVS.BOATS

0 Comments

Share your thoughts

FAQ

What is Pharvaris NV stock price today?▼
The current price of PHVS is $36.22 USD — it has increased by +1.57% in the past 24 hours. Watch Pharvaris NV stock price performance more closely on the chart.
What is Pharvaris NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pharvaris NV stocks are traded under the ticker PHVS.
Is Pharvaris NV stock price growing?▼
PHVS stock has risen by +2.55% compared to the previous week, the month change is a +6.94% rise, over the last year Pharvaris NV has showed a +64.79% increase.
What is Pharvaris NV market cap?▼
Today Pharvaris NV has the market capitalization of 2.54B
When is the next Pharvaris NV earnings date?▼
Pharvaris NV is going to release the next earnings report on November 18, 2026.
What were Pharvaris NV earnings last quarter?▼
PHVS earnings for the last quarter are -0.8 USD per share, whereas the estimation was -0.75 USD resulting in a -7.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pharvaris NV revenue for the last year?▼
Pharvaris NV revenue for the last year amounts to 0 USD.
What is Pharvaris NV net income for the last year?▼
PHVS net income for the last year is -202.18M USD.
How many employees does Pharvaris NV have?▼
As of September 04, 2026, the company has 129 employees.
In which sector is Pharvaris NV located?▼
Pharvaris NV operates in the Health & Wellness sector.
When did Pharvaris NV complete a stock split?▼
Pharvaris NV has not had any recent stock splits.
Where is Pharvaris NV headquartered?▼
Pharvaris NV is headquartered in Leiden, Netherlands.